MoonLake Immunotherapeutics (MLTX) Key Metrics
MLTX valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $812.8M
- Enterprise value
- $662.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 2.6 10-yr median 6.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.08
MLTX key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsMLTX valuation Price multiples at each fiscal year-end price.
MLTX returns How much profit the business earns on the capital it uses.
MLTX per-share figures Results divided by the shares outstanding at year-end.
MLTX financial health Debt, liquidity and how easily interest is covered.
MLTX efficiency & capital use Working capital cycle and where the cash goes.
MLTX valuation history
MLTX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MLTX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MLTX cash returned to shareholders
MLTX price vs earnings per share
MLTX key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $849.6M | $3.40B | $2.97B | $308.3M | $365.2M | — |
| Enterprise value | $531.4M | $2.96B | $2.46B | $236.5M | $372.2M | — |
| Price / book | 2.8 | 7.6 | 6.0 | 6.3 | — | — |
| Earnings yield | −26.8% | −3.5% | −1.2% | −20.9% | −1.2% | — |
| Free cash flow yield | −23.1% | −3.4% | −1.5% | −18.1% | −9.6% | — |
| Dividend yield | — | — | — | — | 0.0% | — |
| Shareholder yield (dividends + buybacks) | — | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Share price at fiscal year-end | $13.18 | $54.15 | $60.39 | $10.50 | $9.89 | $11.37 |
| Per share | ||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Earnings per share | −$3.53 | −$1.89 | −$0.73 | −$2.20 | −$0.12 | — |
| Operating cash flow per share | −$3.04 | −$1.85 | −$0.87 | −$1.90 | −$0.95 | — |
| Free cash flow per share | −$3.04 | −$1.86 | −$0.88 | −$1.90 | −$0.95 | — |
| Cash per share | $6.11 | $7.13 | $10.40 | $2.46 | $0.22 | — |
| Book value per share | $4.72 | $7.11 | $10.09 | $1.67 | −$0.32 | — |
| Tangible book value per share | $4.72 | $7.11 | $10.09 | $1.67 | −$0.32 | — |
| Dividends per share | — | — | — | — | $0.00 | — |
| Capex per share | $0.00 | $0.01 | $0.01 | $0.00 | $0.00 | — |
| Debt per share | $1.17 | $0.05 | $0.08 | $0.01 | $0.41 | — |
| Shares outstanding | 64.5M | 62.9M | 49.1M | 29.4M | 36.9M | — |
| Change in shares outstanding | +2.5% | +28.0% | +67.3% | −20.5% | — | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −60.5% | −25.2% | −13.2% | −346.3% | — | −0.1% |
| Return on invested capital (ROIC) | — | — | — | — | — | −0.1% |
| Return on assets (ROA) | −50.4% | −23.7% | −11.9% | −149.1% | −7.2% | −0.1% |
| Return on tangible assets | −53.6% | −24.9% | −6.8% | −83.9% | −46.9% | −0.1% |
| Financial health | ||||||
| Total debt | $75.7M | $2.8M | $3.7M | $282,580 | $15.0M | $58,063 |
| Cash & short-term investments | $394.0M | $448.0M | $511.0M | $72.1M | $8.0M | $1.3M |
| Net debt | −$318.3M | −$445.2M | −$507.3M | −$71.8M | $7.0M | −$1.3M |
| Debt / equity | 0.25 | 0.01 | 0.01 | 0.01 | — | 0.00 |
| Debt / assets | 0.18 | 0.01 | 0.01 | 0.00 | 1.55 | 0.00 |
| Current ratio | 9.27 | 21.11 | 51.59 | 9.98 | 0.46 | 12.93 |
| Quick ratio | 9.27 | 21.11 | 51.59 | 9.98 | 0.39 | 12.93 |
| Interest coverage | -33.8 | — | — | -110.0 | — | — |
| Working capital | $376.2M | $451.8M | $504.2M | $68.8M | −$11.5M | $1.5M |
| Invested capital | −$13.8M | $1.6M | −$11.6M | −$22.9M | −$4.7M | $111.2M |
| Tangible asset value | $304.5M | $453.4M | $513.5M | $68.8M | −$11.6M | $112.5M |
| Net current asset value | $301.7M | $449.7M | $501.1M | $68.4M | −$11.7M | −$2.5M |
| Graham net-net per share | $4.31 | $6.77 | $10.15 | $2.19 | −$0.34 | — |
| Capital allocation | ||||||
| Dividends paid | — | — | — | — | $51,915 | — |
| Share buybacks (net) | — | $50 | $0 | $0 | $6,202 | — |
| Capex / depreciation | 0.01 | 0.38 | 0.77 | 0.10 | 8.50 | 0.00 |
| Efficiency | ||||||
| Days of inventory on hand | — | — | — | — | 97,082.2 | — |
| Days payables outstanding | 2,588.5 | 1,336.8 | 20,976.7 | 18,910.9 | 90,539.2 | — |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Payables turnover | 0.14 | 0.27 | 0.02 | 0.02 | 0.00 | — |
| Inventory turnover | — | — | — | — | 0.00 | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $3.9M | $2.0M | $636,996 | $182,952 | $148,774 | — |
| Average payables | $18.6M | $5.1M | $756,196 | $640,275 | $1.2M | — |
| Average inventory | — | — | — | — | $1.3M | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from MLTX's annual financial statements (latest annual report filed February 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MLTX valuation and financial ratios
MoonLake Immunotherapeutics earned a return on equity of −60.5% in fiscal 2025. It ended the year with $75.7 million of debt and $394.0 million in cash and short-term investments, a net cash position of $318.3 million.
See the MLTX income statement, the MLTX chart for price history, or the MLTX stock overview for the latest quote and news.
MLTX key metrics FAQ
What is MoonLake Immunotherapeutics's return on equity?
MoonLake Immunotherapeutics's return on equity (ROE) was −60.5% in fiscal 2025: net income of -$227.3 million on average shareholders' equity of $375.7 million.
How much debt does MoonLake Immunotherapeutics have?
MoonLake Immunotherapeutics had total debt of $75.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.25 and more cash than debt.
What is MoonLake Immunotherapeutics's free cash flow yield?
MoonLake Immunotherapeutics generated -$196.0 million of free cash flow in fiscal 2025, a free cash flow yield of −23.1% on its market value at year-end ($849.6 million).
What is MoonLake Immunotherapeutics's current ratio?
MoonLake Immunotherapeutics's current ratio was 9.27 at the end of fiscal 2025: current assets were 9.27 times current liabilities.